Related Experiment Video
Updated: Aug 5, 2026
3D Whole-heart Myocardial Tissue Analysis
Published on: April 12, 2017
Myocardial Fibrosis in Hypertrophic Cardiomyopathy: Leveraging Quantitative Imaging and Artificial Intelligence for
Yaqin Yang1, Yuwei Bao1, Jun Zhang1
1Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, Hubei, China.
Insights
Hypertrophic cardiomyopathy (HCM) management is evolving with advanced imaging and AI. These innovations improve early detection, risk stratification, and targeted therapies for better patient outcomes.
Area of Science:
- Cardiology
- Medical Imaging
- Artificial Intelligence
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart disease linked to myocardial fibrosis.
- Myocardial fibrosis severity is a key predictor of adverse outcomes like sudden cardiac death and heart failure.
- Current HCM management is shifting towards a multidimensional approach integrating imaging, molecular, and functional assessments.
Purpose of the Study:
- To discuss advancements in multimodal imaging for HCM.
- To review AI-driven innovations in HCM diagnostics and risk stratification.
- To highlight the integration of imaging and AI for improved clinical decision-making and patient care.
Main Methods:
- Comprehensive review of multimodal imaging technologies in HCM.
- Analysis of artificial intelligence applications in HCM diagnostics and prognostication.
- Exploration of AI-based predictive modeling for risk stratification and therapeutic guidance.
Main Results:
- Multimodal imaging offers enhanced characterization beyond morphology.
- AI facilitates intelligent diagnostics, precise risk stratification, and personalized therapies.
- Integration of imaging and AI transforms HCM management into a data-driven framework.
Conclusions:
- Advancements in imaging and AI are revolutionizing hypertrophic cardiomyopathy care.
- An integrated approach optimizes early detection, intervention, and prevention strategies.
- AI-powered analytics and precision medicine enhance clinical decision-making for HCM patients.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by asymmetric myocardial hypertrophy and is closely linked with myocardial fibrosis. The level and severity of myocardial fibrosis are independent risk factors for adverse clinical outcomes, including being closely related to sudden cardiac death, heart failure progression, and all-cause mortality. Advances in imaging technology have expanded HCM management beyond standard morphological assessment into a multidimensional paradigm that integrates molecular characterization, functional evaluation, and prognostic stratification. This paradigm shift supports an integrated clinical approach that enables early detection, targeted therapeutic intervention, and risk-adapted prevention strategies. Innovations in artificial intelligence (AI) are further transforming HCM management into an intelligent framework driven by data analytics, predictive modeling, and precision-guided interventions. Building on the pathophysiological basis of myocardial fibrosis, this review presents a comprehensive discussion of transformative developments in multimodal imaging technologies and the associated clinical applications, supported by an in-depth analysis of the recent AI-based advances in intelligent diagnostics, risk stratification, and therapies. Collectively, these concepts aim to optimize clinical decision-making and improve patient care practices.
